Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate change in weight as a result of switching
from quetiapine to ziprasidone, in subjects with schizophrenia or schizoaffective disorder
who have failed to achieve a satisfactory clinical response to quetiapine due to lack of
efficacy or poor tolerability.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.